Insmed Discontinues Brensocatib Development for Hidradenitis Suppurativa After Phase 2b Trial Failure
核心洞察
Insmed's Phase 2b CEDAR study evaluating brensocatib in moderate to severe hidradenitis suppurativa (搜索) failed to meet primary and secondary efficacy endpoints.
The 214-patient randomized trial showed brensocatib performed worse than placebo, with inflammatory count reductions of 45.5% and 40.3% versus 57.1% for placebo.
Despite the efficacy failure, brensocatib maintained a consistent safety profile with no new safety signals identified at doses up to 40 mg.
Insmed Incorporated announced on April 7 that its Phase 2b CEDAR study evaluating brensocatib in adult patients with moderate to severe hidradenitis suppurativa (搜索) (HS) failed to meet its primary or secondary efficacy endpoints, leading the company to discontinue the development program for this indication.
Trial Results Show Inferior Performance to Placebo
The randomized, double-blind CEDAR study enrolled 214 patients across 72 global sites to evaluate brensocatib's efficacy in treating HS. In both the 10 mg and 40 mg treatment arms, brensocatib failed to demonstrate a significant advantage over placebo in reducing the total count of abscesses and inflammatory nodules, the study's primary endpoint.
Clinical data at Week 16 revealed unexpected results, with patients receiving brensocatib showing inferior outcomes compared to placebo. The 10 mg brensocatib group experienced a 45.5% reduction in inflammatory counts, while the 40 mg group saw a 40.3% reduction. In contrast, the placebo group achieved a substantially higher reduction of 57.1%.
Safety Profile Remains Consistent
Despite the efficacy disappointment, brensocatib maintained a consistent safety profile throughout the trial. No new safety signals were identified, even at the 40 mg dosage, which represented the highest dose studied by Insmed to date. This safety consistency aligns with findings from previous brensocatib trials.
Company Response and Future Plans
Following these results, Insmed has made the strategic decision to discontinue the brensocatib development program for HS treatment. The company expressed gratitude to study participants and investigators who contributed to the CEDAR trial and indicated plans to share the complete dataset at a future medical congress.
Insmed continues to focus on developing and commercializing therapies for patients with rare and serious diseases, with brensocatib and Treprostinil Palmitil Inhalation Powder remaining key assets in its pipeline for other indications.